Fresh off an $18 million fundraise, biomarker testing company Cleveland HeartLab plans today to sign a lease for 27,000 square feet of new office space.
HeartLab CEO Jake Orville told MedCity News in July about the company’s intention to lease new space in Cleveland’s growing Health-Tech Corridor between downtown and University Circle. Now, those plans will come to fruition with the signing of a 10-year lease, The Plain Dealer reported.
The company has been occupying about 7,000 square feet on the Cleveland Clinic campus, but has outgrown the space due to rapid demand for its biomarker tests. HeartLab has grown from eight to nearly 80 employees in less than two years, Orville said last month.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A Cleveland Clinic spinoff company, HeartLab is a clinical reference laboratory that does an array of lipid and inflammation tests for clients, and offers a total of about 70 tests. The star of its five-biomarker inflammation panel is a test called CardioMPO, which measures cardiac inflammation marker myeloperoxidase. A high level of MPO indicates that a patient has a higher risk of suffering a heart attack or stroke.
